Florian Fischer

Affimed NV Niederlassung Deutschland discovers and develops antibody-based therapeutic drugs. The firm generates and develops a pipeline of antibody product candidates based on proprietary technology platform. It offer therapeutic drugs that target autoimmune diseases and tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany.

Vectura GmbH manufactures and develops pharmaceutical therapies for airways diseases. It offers dry powder formulation technology, device technology, and development capabilities. The company was founded by Gerhard Scheuch in 1997 and is headquartered in Gemünden, Germany.

KPMG LLP engages in the provision of audit, tax, and advisory services. It serves the banking and capital markets, building, construction and real estate, consumer and retail, energy, natural resources and chemicals, financial services, government and public sector, healthcare and life sciences, industrial manufacturing, insurance, media and entertainment, private equity, technology, telecommunications, and venture capital industries. The company was founded in 1987 and is headquartered in New York, NY.

Vivendy Therapeutics Ltd. develops enzyme replacement therapy and biological products. It has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity-enhancing the efficacy of the therapy in MPS IVA significantl. The company was founded in March 2006 and is headquartered in Basel, Switzerland.

MedVenture Partners GmbH engages in the provision of corporate finance and strategy advisory services. The firm focuses on life sciences and healthcare. It specializes in corporate finance, economic evaluation of health technologies, corporate strategy, as well as part-time and interim management. The company was founded by Florian Fischer on May 28, 2002 and is headquartered in Pullach, Germany.

Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA.

Part of Affimed NV, AbCheck sro is a Czech company that specializes in discovering and optimizing human therapeutic antibodies using advanced technology platforms. The company is based in Plzen, Czechia. The company offers personalized approaches to meet the specific needs of its customers and designs high-quality leads using both cutting-edge and classical technologies. AbCheck has proven its capabilities in multiple partnerships and is a wholly-owned subsidiary of Affimed GmbH.